Phase 4Completed
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (Optimize@Home)
Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.
- Sponsor
- University Medical Center Groningen (Academic or other)
- Enrollment
- 12 enrolled
- Conditions
- Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3
- Interventions
- Empagliflozin 10 MG; Finerenone; Withings BPM Connect; Withings Body; PeeSpot Urine Collection Device; Hem-Col Capillary Blood Collection Device; Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
- Ages
- adults, older adults
- Registry
- NCT06094920
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria. The main questions it aims to answer are: * What is the feasibility (and advantages) of remote clinical trial conduct with multiple medications in patients with type 2 diabetes and elevated albuminuria? * What is the individual response to the SGLT2 inhibitor empagliflozin in urine albumin-creatinine ratio? * What is the individual response to the SGLT2 inhibitor empagliflozin in systolic blood pressure, body weight, eGFR, and fasting plasma glucose? * Can suboptimal treatment responses to empagliflozin be overcome by the addition or substitution with finerenone? Participants will collect all study data in the comfort of their own environments * First-morning void urine samples * Capillary blood samples * Blood pressure * Body weight Participants will be assigned to a 3-week treatment period with empagliflozin 10 mg/day. Based on the albuminuria response after 2 weeks, participants will be allocated to one of three treatment…
Primary outcomes
- Questionnaire results
- Remote urine collection
- Remote blood pressure measurements
- Remote body weight measurements
History
Last registry update
Primary completion
Started
Registered